Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  Mazdutide (IBI362 / LY3305677)

Research reference — not for sale

Mazdutide (IBI362 / LY3305677)

A

lead outcome

Weight loss (obesity, no diabetes)

grades vary by outcome ↓

Peptide

also called — Mazdutide · development codes IBI362 and LY3305677 · a GLP-1 / glucagon (GCGR) dual receptor agonist · an oxyntomodulin (OXM) analog. Marketed in China (Innovent). INCI: none

metabolicweight lossglycaemic (T2D)(glucagon-driven:) energy expenditurehepatic fatvisceral-fat reduction

Survodutide's twin — same mechanism, but this one is already approved. Three points make this entry land: (1) it's the same GLP-1 / glucagon dual class as Survodutide (#6), but built as an oxyntomodulin analog — and, crucially, it is the first GLP-1/glucagon dual agonist approved anywhere in the world (China NMPA, 2025); (2) its Phase 3 GLORY-2 hit ~20.1% weight loss — matching the tirzepatide tier — with just a two-step titration; (3) in a head-to-head trial it beat semaglutide (DREAMS-3). This is the entry that shows "investigational vs approved" within the same mechanism.

In brief

Mazdutide is a GLP-1 / glucagon dual-agonist peptide — the same mechanism as Survodutide (#6) — but designed as an oxyntomodulin analog and co-developed by Innovent and Eli Lilly. Its defining fact: in June 2025 it became the first GLP-1/glucagon dual agonist approved anywhere in the world (China NMPA, for weight management; T2D followed in September). The glucagon arm gives it the class-typical extras — increased energy expenditure and hepatic fat oxidation, plus notable visceral-fat reduction — on top of GLP-1 appetite suppression. Efficacy is strong: GLORY-2 reached ~20.1% weight loss at over 60 weeks (the tirzepatide tier) with only a two-step dose titration, and in the DREAMS-3 head-to-head it beat semaglutide on both weight and HbA1c. Tolerability is the usual GLP-1 GI profile (nausea/diarrhea/vomiting, mostly mild-moderate and transient; ~2.9% discontinuation in GLORY-2). The honest caveat: the pivotal evidence is entirely in Chinese populations, and it is approved only in China — global trials/approvals are still pending.

Legal standing, by region

European Union

Not approved

not approved outside China; investigational elsewhere. Not a cosmetic; no compounding pathway.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Weight loss (obesity, no diabetes)

Approved, strong efficacy — but pivotal data are Chinese-population only; not approved/validated elsewhere yet. The "A" is region-qualified

Phase 3 GLORY-2 (2025): ~20.1% at / 60 wk; GLORY-1 (NEJM 2025) positive → China NMPA approval

A

Glycemic control (T2D)

Approved for T2D in China; head-to-head win is notable; same population caveat

DREAMS-1/-2 (Nature, 2025) vs placebo; DREAMS-3 head-to-head superior to semaglutide → NMPA T2D approval

A

Visceral / hepatic fat

Consistent metabolic benefits reported; dedicated MASH-histology program less developed than Survodutide's

Glucagon-arm effect; reported waist-circumference, lipid, BP improvements

B

Cardiometabolic risk factors (BP, lipids, waist)

Improvements reported alongside weight/glucose; long-term CV-outcome trial not the headline here

Phase 3 secondary endpoints

B

Safety / tolerability

GI predominant (nausea ~21–41%, diarrhea, vomiting — dose-escalation, then settle); mild-moderate; only 2.9% discontinued in GLORY-2; glucagon arm still requires glucose-balanced titration (like all GCGR/GLP-1 duals)

Phase 1b→3 (GLORY/DREAMS)

—

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Mazdutide (IBI362 / LY3305677) changes - nothing else.

Identity

a peptide engineered for weekly subcutaneous dosing, structurally modeled on mammalian oxyntomodulin — a naturally occurring proglucagon-derived hormone that already activates both the GLP-1 and glucagon receptors. Co-developed by Innovent Biologics and Eli Lilly (Lilly China license). Same two-receptor target as Survodutide (#6) — GLP-1 + glucagon, not GIP — but reached via the OXM template.

Mechanism (as proposed)

as an oxyntomodulin analog, mazdutide co-activates GLP-1 (appetite suppression, slowed gastric emptying, insulin secretion, glucose lowering) and glucagon (GCGR) (increased energy expenditure / thermogenesis + hepatic fat oxidation + visceral-fat mobilisation). The GLP-1 component offsets glucagon's intrinsic glucose-raising tendency — the same balancing act as Survodutide, and the same reason OXM works naturally without worsening glycaemia. The net effect is potent weight loss plus comprehensive metabolic improvement (glucose, lipids, blood pressure, waist).

Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

CAS2259884-03-0

PubChem CID167312357

InChIKeyXRBYWQZGSZWYEJ-HMQIFOERSA-N

SMILESC[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC8=CNC=N8)N)O

via PubChem exact-name match (Mazdutide) · high confidence

Sources — 5 cited

01Innovent Biologics — NMPA approvals: weight management (June 2025), T2D (Sept 2025); GLORY-2 topline (Nov 2025, ~20.1%).

02GLORY-1 — Phase 3 obesity, NEJM (May 2025).

03DREAMS-1 & DREAMS-2 — Phase 3 T2D, published back-to-back in Nature (2025); DREAMS-3 head-to-head vs semaglutide (superiority; DDW/Innovent 2025).

04Ji L, et al. IBI362 (LY3305677) weekly GLP-1/glucagon dual agonist, Phase 1b. EClinicalMedicine 2021; and / multiple-ascending-dose Phase 1b, EClinicalMedicine 2022.

05Deng CX, et al. Mazdutide: an emerging GCGR/GLP-1 dual agonist for obesity. World J Pharmacol. 2026; oxyntomodulin dual-agonist rationale (Wharton, Diab Obes Metab 2026).

Updated 2026-07-13 (China-approved; watch for global (non-Chinese) trials and any ex-China regulatory filing, which would change the region-qualified grades)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

Survodutide (BI 456906)B

Explore by goal

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.